Shengqing Stan Gu

6PUBLICATIONS
92CO-AUTHORS
Molecular targetsMedical molecular engineering of nucleic acids and proteinsHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jul 14, 2025
Selective Alanine Transporter Utilization Is a Therapeutic Vulnerability in ARID1A-Mutant Ovarian Cancer.

Hao Nie, Liping Liao, Rafal J Zielinski

|Feb 06, 2023
Discovery of Targets for Immune-Metabolic Antitumor Drugs Identifies Estrogen-Related Receptor Alpha.

Avinash Sahu, Xiaoman Wang, Phillip Munson

|Oct 20, 2022
A Molecular Switch between Mammalian MLL Complexes Dictates Response to Menin-MLL Inhibition.

Yadira M Soto-Feliciano, Francisco J Sánchez-Rivera, Florian Perner

|Oct 14, 2022
Machine learning on syngeneic mouse tumor profiles to model clinical immunotherapy response.

Zexian Zeng, Shengqing Stan Gu, Cheryl J Wong

|Oct 11, 2022
Hippo Signaling Pathway Regulates Cancer Cell-Intrinsic MHC-II Expression.

Zexian Zeng, Shengqing Stan Gu, Nofal Ouardaoui

|Jun 23, 2021
Computational modeling of ovarian cancer dynamics suggests optimal strategies for therapy and screening.

Shengqing Gu, Stephanie Lheureux, Azin Sayad

Pageof 1